Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma

International Journal of Cancer

Volumn 74, Issue 5, 1997, Pages 535-539

  Straume, Oddbjørn ^a   Akslen, Lars A ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; FEMALE; HEAD AND NECK TUMOR; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENT CANCER;

CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030659080     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19971021)74:5<535::AID-IJC10>3.0.CO;2-5     Document Type: Article

References (27)

1. AKSLEN, L.A. and MØRKVE, O., Expression of p53 protein in cutaneous melanoma. Int. J. Cancer, 52, 13-16 (1992).
2. BARTKOVA, J., LUKAS, J., GULDBERG, P., ALSNER, J., KIRKIN, A.F., ZEUTHEN, J. and BARTEK, J., The p 16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res., 56, 5475-5483 (1996).
3. BARTSCH, D., SHEVLIN, D.W., CALLERY, M.P., NORTHON, J.A. JR. and GOODFELLOW, P.J., Reduced survival in patients with ductal pancreatic adenoearcinoma associated with CDNK2 mutation. J. nat. Cancer Inst., 88, 680-682 (1996).
4. BRASH, D.E., RUDOLPH, J.A., SIMON, J.A., MCKENNA, G.J., BADEN, H.P., HALPERIN, A.J. and PONTÉN, J., A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc. nat. Acad. Sci. (Wash.), 88, 10124-10128 (1991).
5. CASTRASENA, J.S., RUBIO, M.-P., VASQUES, J.J., IDIDATE, M., SOBER, A.J., SEIZINGER, B.R. and BARNHILL, R.L., Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma. Int. J. Cancer, 55, 562-565 (1993).
6. DOCKHORN-DWORNICZAK, B., YANDELL, D.W., MERRITT, V., BOECKER, W. and POREMBA, C., p53 mutation in primary malignant melanoma. Proc. Amer. Assoc. Cancer Res., 34, 111 (abstract) (1993).
7. INK4b genes, as well as neighbouring 9p21 markers, in sporadic melanoma. Cancer Res., 56, 5023-5032 (1996).
8. FLØRENES, V.A., HOLM, R. and FODSTAD, Ø., Accumulation of p53 protein in human malignant melanoma. Relationship to clinical outcome. Melanoma Res., 5, 183-187 (1995).
9. FLØRENES, V.A., ØYJORD, T., HOLM, R., SKREDE, M., BØRRESEN, A.L., NESLAND, J.M. and FODSTAD, Ø., TP53 allele loss, mutations, and expression in malignant melanoma. Brit. J. Cancer, 69, 253-259 (1994).
10. GRUIS, N.A. and 12 OTHERS. Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Amer. J. Pathol., 146, 1199-1206 (1995).
11. HARTMANN, A., BLASZYK, H., CUNNINGHAM, J.S., MCGOVERN, R.M., SCHROEDER, J.S., HELANDER, S.D., PITTELKOW, M.R., SOMMER, S.S. and KOVACH, J.S., Overexpression and mutations of p53 in metastatic malignant melanomas. Int. J. Cancer, 67, 313-317 (1996).
12. HUSSUSSIAN, C.J., STRUEWING, J.P., GOLDSTEIN, A.M., HIGGINS, P.A.T., ALLY, D.S., SHAEAN, M.D., CLARK, JR. W.H., TUCKER, M.A. and DRACOPOLI, N.C., Germline p16 mutations in familial melanoma. Nature (Genet.) 8, 5-21 (1994).
13. KORABIOWSKA, M., BRINCK, U., HOENIG, J.F., BARTKOWSKI, S.B., KELLNER, S., MARX, D. and SCHAUER, A., Significance of p53 antigen in malignant melanomas and naevi of the head and neck area. Anticancer Res., 15, 885-890 (1995).
14. LASSAM, N.J., FROM, L. and KAHN, H.J., Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res., 53, 2235-2238 (1993).
15. LEVINE, A.J., MOMAND, J. and FINLAY, C.A., The p53 tumor suppressor gene. Nature (Lond.), 51, 453-456 (1991).
16. LÜBBE, J., REICHEL, M., BURG, G. and KLEIHUES, P., Absence of p53 gene mutations in cutaneous melanoma. J. Invest. Dermatol., 102, 819-821 (1994).
17. MAELANDSMO, G.M., FLØRENES, V.A., HOVIG, E., ØYJORD, T., ENGEBRAATEN, O., HOLM, R., BØRRESEN, A.-L. and FODSTAD, Ø., Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas. Brit. J. Cancer, 73, 909-916 (1996).
18. MARKS, R., An overview of skin cancers. Incidence and causation. Cancer, 75, 607-612 (1995).
19. REED, J.A., LOGANZO, F. JR., SHEA, C.R., WALKER, G.J., FLORES, J.F., GLANDENING, M., BOGDANY, J.K., SHIEL, M.J., HALUSKA, F.G., FOUNTAIN, J.W. and ALBINO, A.P., Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res., 55, 2713-2718 (1995).
20. SAENZ-SANTAMARJA, M.C., MCNUTT, N.S. and SHEA, C.R., Immunohistochemical expression of retinoblastoma protein in cutaneous melanomas. Brit. J. Dermatol., 133, 890-895 (1995).
21. INK4 expression in primary lung cancers and cell lines. Cancer Res., 55, 505-509 (1995).
22. SPARROW, L.E., ENGLISH, D.R., HEENAN, P.J., DAWKINS, H.J. and TARAN, J., Prognostic significance of p53 over-expression in thin melanomas. Melanoma Res., 5, 387-392 (1995).
23. STRAUME, O. and AKSLEN, L.A., Independent prognostic importance of vascular invasion in nodular melanomas. Cancer, 78, 1211-1219 (1996).
24. STRETCH, J.R., GATTER, K.C., RALFKIAER, E., LANE, D.P. and HARRIS, A., Expression of mutant p53 in melanoma. Cancer Res., 51, 5976-5979 (1991).
25. WEISS, J., HEINE, M., KØRNER, B., PILCH, H. and JUNG, E.G., Expression of p53 protein in malignant melanoma: Clinopathological and prognostic implications. Brit. J. Dermatol., 133, 23-31 (1995).
26. WEISS, J., SCHWECHHEIMER, K., CAVENEE, W.K., HERLYN, M. and ARDEN, K.C., Mutation and expression of the p53 gene in malignant melanoma cell lines. Int. J. Cancer, 54, 693-699 (1993).
27. YAMAMOTO, M., TAKAHASHI, H., SAITOH, K., TAKASHI, H. and TAKAHASHI, M., Expression of the p53 protein in malignant melanoma as a prognostic indicator. Arch. Dermatol., Res., 287, 146-151 (1995).